Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Reiberger T, et al. Among authors: datz c. Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Epub 2017 Oct 23. Wien Klin Wochenschr. 2017. PMID: 29063233 Free PMC article.
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Müller C, Hackl F, Rainer W, Watkins-Riedel T, Lin W. Ferenci P, et al. Among authors: datz c. J Viral Hepat. 1999 Jul;6 Suppl 1:53-8. doi: 10.1046/j.1365-2893.1999.00005.x. J Viral Hepat. 1999. PMID: 10760037 Clinical Trial.
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Müller C, Hackl F, Rainer W, Watkins-Riedel T, Lin W, Krejs GJ, Gangl A; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: datz c. Eur J Gastroenterol Hepatol. 2001 Jun;13(6):699-705. doi: 10.1097/00042737-200106000-00014. Eur J Gastroenterol Hepatol. 2001. PMID: 11434597 Clinical Trial.
Mutations of the HFE gene in patients with hepatocellular carcinoma.
Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schöniger-Hekele M, Hackl F, Polli C, Rasoul-Rockenschaub S, Müller C, Wrba F, Gangl A, Ferenci P. Cauza E, et al. Among authors: datz c. Am J Gastroenterol. 2003 Feb;98(2):442-7. doi: 10.1111/j.1572-0241.2003.07222.x. Am J Gastroenterol. 2003. PMID: 12591066
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.
Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Tilg H, et al. Among authors: datz c. J Hepatol. 2003 Apr;38(4):419-25. doi: 10.1016/s0168-8278(02)00442-7. J Hepatol. 2003. PMID: 12663232 Clinical Trial.
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Stauber RE, Hofer H, Hackl F, Schütze K, Datz C, Hegenbarth K, Jessner W, Steindl-Munda P, Peter F; Austrian Hepatitis Study Group. Stauber RE, et al. Among authors: datz c. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):530-5. doi: 10.1007/BF03217706. Wien Klin Wochenschr. 2004. PMID: 15471180 Clinical Trial.
192 results